Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Exploiting the 1-(4-fluorobenzyl)piperazine fragment for the development of novel tyrosinase inhibitors as anti-melanogenic agents: Design, synthesis, structural insights and biological profile.

Ielo L, Deri B, Germanò MP, Vittorio S, Mirabile S, Gitto R, Rapisarda A, Ronsisvalle S, Floris S, Pazy Y, Fais A, Fishman A, De Luca L.

Eur J Med Chem. 2019 Sep 15;178:380-389. doi: 10.1016/j.ejmech.2019.06.019. Epub 2019 Jun 6.

PMID:
31202126
2.

Correction to Targeting Tyrosinase: Development and Structural Insights of Novel Inhibitors Bearing Arylpiperidine and Arylpiperazine Fragments.

Ferro S, Deri B, Germanò MP, Gitto R, Ielo L, Buemi MR, Certo G, Vittorio S, Rapisarda A, Pazy Y, Fishman A, De Luca L.

J Med Chem. 2019 Feb 14;62(3):1697. doi: 10.1021/acs.jmedchem.9b00105. Epub 2019 Jan 30. No abstract available.

PMID:
30698018
3.

Filling the Void: Introducing Aromatic Interactions into Solvent Tunnels To Enhance Lipase Stability in Methanol.

Gihaz S, Kanteev M, Pazy Y, Fishman A.

Appl Environ Microbiol. 2018 Nov 15;84(23). pii: e02143-18. doi: 10.1128/AEM.02143-18. Print 2018 Dec 1.

4.

Targeting Tyrosinase: Development and Structural Insights of Novel Inhibitors Bearing Arylpiperidine and Arylpiperazine Fragments.

Ferro S, Deri B, Germanò MP, Gitto R, Ielo L, Buemi MR, Certo G, Vittorio S, Rapisarda A, Pazy Y, Fishman A, De Luca L.

J Med Chem. 2018 May 10;61(9):3908-3917. doi: 10.1021/acs.jmedchem.7b01745. Epub 2018 Apr 20. Erratum in: J Med Chem. 2019 Feb 14;62(3):1697.

PMID:
29634898
5.

Altering 2-Hydroxybiphenyl 3-Monooxygenase Regioselectivity by Protein Engineering for the Production of a New Antioxidant.

Bregman-Cohen A, Deri B, Maimon S, Pazy Y, Fishman A.

Chembiochem. 2018 Mar 16;19(6):583-590. doi: 10.1002/cbic.201700648. Epub 2018 Feb 8.

PMID:
29297973
6.

Identical phosphatase mechanisms achieved through distinct modes of binding phosphoprotein substrate.

Pazy Y, Motaleb MA, Guarnieri MT, Charon NW, Zhao R, Silversmith RE.

Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1924-9. doi: 10.1073/pnas.0911185107. Epub 2010 Jan 14.

7.

Matching biochemical reaction kinetics to the timescales of life: structural determinants that influence the autodephosphorylation rate of response regulator proteins.

Pazy Y, Wollish AC, Thomas SA, Miller PJ, Collins EJ, Bourret RB, Silversmith RE.

J Mol Biol. 2009 Oct 9;392(5):1205-20. doi: 10.1016/j.jmb.2009.07.064. Epub 2009 Jul 28.

8.

Single MHC mutation eliminates enthalpy associated with T cell receptor binding.

Miller PJ, Pazy Y, Conti B, Riddle D, Appella E, Collins EJ.

J Mol Biol. 2007 Oct 19;373(2):315-27. Epub 2007 Jul 26.

9.

Structural elements responsible for conversion of streptavidin to a pseudoenzyme.

Eisenberg-Domovich Y, Pazy Y, Nir O, Raboy B, Bayer EA, Wilchek M, Livnah O.

Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):5916-21. Epub 2004 Apr 12.

10.

Dimer-tetramer transition between solution and crystalline states of streptavidin and avidin mutants.

Pazy Y, Eisenberg-Domovich Y, Laitinen OH, Kulomaa MS, Bayer EA, Wilchek M, Livnah O.

J Bacteriol. 2003 Jul;185(14):4050-6.

11.

Structure-based rational design of streptavidin mutants with pseudo-catalytic activity.

Pazy Y, Raboy B, Matto M, Bayer EA, Wilchek M, Livnah O.

J Biol Chem. 2003 Feb 28;278(9):7131-4. Epub 2002 Dec 18.

12.

Ligand exchange between proteins. Exchange of biotin and biotin derivatives between avidin and streptavidin.

Pazy Y, Kulik T, Bayer EA, Wilchek M, Livnah O.

J Biol Chem. 2002 Aug 23;277(34):30892-900. Epub 2002 Jun 7.

13.

Crystallization and preliminary X-ray analysis of W120K mutant of streptavidin.

Pazy Y, Laitinen OH, Ravoy B, Kulomaa MS, Wilchek M, Bayer EA, Livnah O.

Acta Crystallogr D Biol Crystallogr. 2001 Dec;57(Pt 12):1885-6. Epub 2001 Nov 21.

PMID:
11717505

Supplemental Content

Support Center